 |
|
Malaria Vaccine Initiative And Apovia Inc. Partner To Pursue Rapid Development Of Novel Malaria Vaccine
January 26, 2001A public-private partnership announced today promises to bring a powerful new malaria vaccine into human trials this year. The partnership between a San Diego-based biotechnology company, Apovia Inc., and the Malaria Vaccine Initiative at PATH (Program for Appropriate Technology in Health) is a multi-million dollar, multi-year agreement. The partnership’s goal is the manufacturing and licensing of a vaccine that could save the lives of children in the developing world, especially in Africa, where as many as three children per minute die from the disease.
“We’re excited to support a company with an extremely promising malaria vaccine technology, especially since the return on our investment will go to the public sector,” said Dr. Regina Rabinovich, director of the Malaria Vaccine Initiative (MVI). “Apovia is bringing the innovation and nimbleness of the biotechnology sector to the complex field of malaria vaccine development.”
“MVI’s participation in developing this vaccine brings not only financial support, but also scientific support and development expertise,” said Martin Steiner, CEO of Apovia AG, the parent company of Apovia Inc. “This partnership will lead to the validation of our technology and our product.”
Apovia Inc. is a biotechnology company that has made malaria vaccine development a primary focus of its work. The Malaria Vaccine Initiative at PATH is a program dedicated to accelerating the development of promising malaria vaccine candidates and to ensuring their availability and accessibility for the developing world. This is MVI’s first major agreement with a private sector company.
In the agreement with MVI, Apovia will provide its novel, proprietary vaccine technology and considerable experience in vaccine development. Explains George Ben Thornton, president of Apovia Inc., “The Apovia candidate vaccine is a virus-like particle that displays pieces of malaria parasite proteins, or antigens. These antigens, which were identified and characterized by Drs. Ruth and Victor Nussenzweig and colleagues at New York University, stimulate the immune system and prime it to fight off the disease in the case of future exposure.”
Apovia Inc. has already tested the vaccine in mice, rabbits, and small primates. “The strength of the response has been nearly unprecedented,” Thornton said. Under the new partnership, the vaccine will next be tested in larger primates and in a human trial in the United States, conducted in collaboration with the National Institutes of Health. If these results are promising, clinical trials in Africa will follow.
MVI will participate in the process of vaccine development, working with Apovia and its collaborators to guide the vaccine through pre-clinical testing, manufacturing, regulatory affairs, initial human trials, and large-scale efficacy trials.
Malaria is a parasitic infection transmitted through the bite of the Anopheles mosquito. The World Health Organization estimates that between 300 and 500 million people are currently infected, and 2.3 billion are at risk. Two million people or more die of malaria every year, and over half of these deaths are of children in sub-Saharan Africa.
Because of the way the malaria parasite develops within its victims, many scientists believe that the most effective vaccine will ultimately have to target more than one stage of its development cycle. “If the Apovia product continues to perform as safely and effectively as expected, it could be a great platform for a such a vaccine,” said Dr. Filip Dubovsky, a senior program officer at MVI.
MVI was created in the belief that the technology and knowledge needed to create a malaria vaccine exist, but that market forces alone will not lead to the aggressive development of a vaccine needed only by developing countries.
PATH established the Malaria Vaccine Initiative through a $50 million award by the Bill & Melinda Gates Foundation. PATH is an international non-profit organization whose mission is to improve health, especially the health of women and children. For further information on MVI, visit the Web site at: www.malariavaccine.org.
Apovia Inc., formed in December 2000 after the acquisition of Immune Complex Corporation by Apovia AG (formerly Evax Technologies AG), is a biotechnology company focused on the development of human vaccines. Apovia AG is headquartered in Martinsreid, Germany, and its US subsidiary, Apovia Inc., is located in San Diego, California.
Noonan Russo Ltd
Apovia Inc. is a biotechnology company that has made malaria vaccine development a primary focus of its work. The Malaria Vaccine Initiative at PATH is a program dedicated to accelerating the development of promising malaria vaccine candidates and to ensuring their availability and accessibility for the developing world. This is MVI’s first major agreement with a private sector company.
In the agreement with MVI, Apovia will provide its novel, proprietary vaccine technology and considerable experience in vaccine development. Explains George Ben Thornton, president of Apovia Inc., “The Apovia candidate vaccine is a virus-like particle that displays pieces of malaria parasite proteins, or antigens. These antigens, which were identified and characterized by Drs. Ruth and Victor Nussenzweig and colleagues at New York University, stimulate the immune system and prime it to fight off the disease in the case of future exposure.”
Apovia Inc. has already tested the vaccine in mice, rabbits, and small primates. “The strength of the response has been nearly unprecedented,” Thornton said. Under the new partnership, the vaccine will next be tested in larger primates and in a human trial in the United States, conducted in collaboration with the National Institutes of Health. If these results are promising, clinical trials in Africa will follow.
MVI will participate in the process of vaccine development, working with Apovia and its collaborators to guide the vaccine through pre-clinical testing, manufacturing, regulatory affairs, initial human trials, and large-scale efficacy trials.
Malaria is a parasitic infection transmitted through the bite of the Anopheles mosquito. The World Health Organization estimates that between 300 and 500 million people are currently infected, and 2.3 billion are at risk. Two million people or more die of malaria every year, and over half of these deaths are of children in sub-Saharan Africa.
Because of the way the malaria parasite develops within its victims, many scientists believe that the most effective vaccine will ultimately have to target more than one stage of its development cycle. “If the Apovia product continues to perform as safely and effectively as expected, it could be a great platform for a such a vaccine,” said Dr. Filip Dubovsky, a senior program officer at MVI.
MVI was created in the belief that the technology and knowledge needed to create a malaria vaccine exist, but that market forces alone will not lead to the aggressive development of a vaccine needed only by developing countries.
PATH established the Malaria Vaccine Initiative through a $50 million award by the Bill & Melinda Gates Foundation. PATH is an international non-profit organization whose mission is to improve health, especially the health of women and children. For further information on MVI, visit the Web site at: www.malariavaccine.org.
Apovia Inc., formed in December 2000 after the acquisition of Immune Complex Corporation by Apovia AG (formerly Evax Technologies AG), is a biotechnology company focused on the development of human vaccines. Apovia AG is headquartered in Martinsreid, Germany, and its US subsidiary, Apovia Inc., is located in San Diego, California.
Noonan Russo Ltd
Malaria Current Events and Malaria News RSSMeasuring and modeling blood flow in malaria
When people have malaria, they are infected with Plasmodium parasites, which enter the body from the saliva of a mosquito, infect cells in the liver, and then spread to red blood cells.
On the Trail of a Vaccine for Lyme Disease: Yale Researchers Target Tick Saliva
A protein found in the saliva of ticks helps protect mice from developing Lyme disease, Yale researchers have discovered. The findings, published in the November 19 issue of Cell Host & Microbe, may spur development of a new vaccine against infection from Lyme disease, which is spread through tick bites.
Research calls for better assessment of tests for tuberculosis, HIV/AIDS and malaria
A rapid and accurate diagnosis is the first step towards treatment in the fight against infectious disease.
Small nanoparticles bring big improvement to medical imaging
If you're watching the complex processes in a living cell, it is easy to miss something important-especially if you are watching changes that take a long time to unfold and require high-spatial-resolution imaging.
Prioritizing low-cost, simple health measures would save 2.5 million child lives a year
Almost a third of the children under age five who die each year could be saved if governments rebalance health spending to ensure low-cost, simple interventions such as safe water and hygiene, bed nets and basic maternal and newborn care, leading aid agency World Vision said today. Currently, 8.8 million children a year die before age five, most of preventable causes.
Drug industry, nonprofits join forces to fight world's neglected diseases
Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year.
U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat
Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.
1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
DNA barcodes: Creative new uses span health, fraud, smuggling, history, more
The scientific ability to quickly and accurately identify species through DNA "barcoding" is being embraced and applied by a growing legion of global authorities - from medical and agricultural researchers to police and customs authorities to palaeontologists and others.
PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines
Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa.
More Malaria Current Events and Malaria News Articles
 |
The Making of a Tropical Disease: A Short History of Malaria (Johns Hopkins Biographies of Disease) by Randall M. Packard (Author) Malaria sickens hundreds of millions of people -- and kills one to three million -- each year. Despite massive efforts to eradicate the disease, it remains a major public health problem in poorer tropical regions. But malaria has not always been concentrated in tropical areas. How did other regions control malaria and why does the disease still flourish in some parts of the globe? From Russia to Bengal to Palm Beach, Randall Packard's far-ranging narrative traces the natural and social forces that help malaria spread and make it deadly. He finds that war, land development, crumbling health systems, and globalization -- coupled with climate change and changes in the distribution and flow of water -- create conditions in which malaria's carrier mosquitoes thrive. The combination of... |
 |
The Malaria Capers : More Tales of Parasites and People, Research and Reality by Robert S. Desowitz (Author) "Reads like a murder mystery. . . . [Desowitz] writes with uncommon lucidity and verse, leaving the reader with a vivid understanding of malaria and other tropical diseases, and the ways in which culture, climate and politics have affected their spread and containment."—New York Times Why, Robert S. Desowitz asks, has biotechnical research on malaria produced so little when it had promised so much? An expert in tropical diseases, Desowtiz searches for answers in this provocative book. . |
 |
Compiled 1981-1984 by Malaria! |
 |
Humanity's Burden: A Global History of Malaria (Studies in Environment and History) by James L.A. Webb Jr. (Author) Humanity's Burden provides a panoramic overview of the history of malaria. It traces the long arc of malaria out of tropical Africa into Eurasia, its transfer to the Americas during the early years of the Columbian exchange, and its retraction from the middle latitudes into the tropics since the late nineteenth century. Adopting a broadly comparative approach to historical patterns and processes, it synthesizes research findings from the natural and social sciences and weaves these understandings into a narrative that reaches from the earliest evidence of malaria infections in tropical Africa up to the present. Written in a style that is easily accessible to non-specialists, it considers the significance of genetic mutations, diet, lifestyle, migration, warfare, palliative and curative... |
 |
First Comes Love, Then Comes Malaria: How a Peace Corps Poster Boy Won My Heart and a Third World Adventure Changed My Life by Eve Brown-Waite (Author) In this laugh-out-loud funny memoir, a pampered city girl falls head over little black heels in love with a Peace Corps poster boy and follows him —literally–to the ends of the earth. Eve Brown always thought she would join the Peace Corps someday, although she secretly worried about life without sushi, frothy coffee drinks and air conditioning. But with college diploma in hand, it was time to put up or shut up. So with some ambivalence she arrives at the Peace Corps office–sporting her best safari chic attire –to casually look into the steps one might take if one were to become a global humanitarian, a la Angelina Jolie. But when Eve meets John, her dashing young Peace Corps recruiter, all her ambivalence flies out the window. She absolutely must join the Peace Corps -... |
![GIANTmicrobes: Malaria (Plasmodium Falciparum) [Toy] [Toy] [Toy]](http://ecx.images-amazon.com/images/I/21rpOp-8iXL._SL160_.jpg) |
GIANTmicrobes: Malaria (Plasmodium Falciparum) [Toy] [Toy] [Toy] by Giant Microbes The tropics have coconuts, soft beaches, clear water, shiny fish, colorful birds, steel drums, umbrella drinks ... and Malaria. Now you can collect a dozen of the most adorable viruses, bacteria, mites, worms and calamities nature ever unleashed. Disturbingly cuddly, Giant Microbes are great learning tools for parents and educators, amusing gifts for anyone with a sense of humor, or just friendly plush companions for those trying to get past their Bacillophobia. Each 5-to-7 inch doll is accompanied by an image of the not-so-cute real microbe it represents, as well as quick facts about the microbe. Antibiotics not required. |
 |
Sea to Summit Mozi Mosquito Net Shelter,Single by Sea to Summit An indispensable item for traveling or backpacking in bug infested regions. Our Mosquito Net shelters are small, light and compact. They come with a handy stuff sack for easing packing and offer tuck-in sides offer extra protection. |
 |
Malaria: Fever Wars Starring: Artist Not Provided |
 |
Molecular Approaches to Malaria by Irwin W. Sherman (Editor) "Molecular Approaches to Malaria" provides an overview of the rapid and significant developments that have occurred in malaria research, including the 2002 genome sequencing of Plasmodium falciparum and its mosquito vector, Anopheles gambiae. This work: provides a concise source of up-to-date research findings; appeals to a diverse audience, including malaria researchers, teachers, investigators, and public health professionals; offers contributions by recognized malaria researchers with practical experience; and, presents comprehensive coverage of topics including a clearly written introduction to Plasmodium molecular biology. |
 |
Revisited by Malaria! |
| © 2009 BrightSurf.com |